By Fineline Cube 
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first‑half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year‑on‑year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China’s leading drugmaker deepens its pivot from generics toward innovation.
1H 2026 Financial Highlights
| Item | 1H 2026 | YoY Change |
|---|---|---|
| Total Operating Revenue | RMB 15.456 bn | ‑1.94% |
| Product Sales Revenue | RMB 13.948 bn | +1.87% |
| Net Profit (attributable) | RMB 4.465 bn | +0.34% |
| R&D Investment | RMB 4.605 bn | +18.96% |
| ‑ of which Expensed R&D | RMB 3.493 bn | +8.21% |
| Innovative Drug Sales | RMB 8.809 bn | +16.38% |
| Generic Drug Sales | RMB 5.139 bn | ‑16.07% |
| Out‑licensing Revenue | RMB 1.422 bn | vs. RMB 1.991 bn in 1H 2025 |
Innovative Drug Mix Accelerates
| Segment | 1H 2026 Revenue | YoY | Share of Innovative Sales |
|---|---|---|---|
| Oncology Innovative Products | RMB 6.265 bn | +2.58% | 71.11% |
| Non‑Oncology Innovative Products | RMB 2.545 bn | +73.97% | 28.89% |
| Total Innovative Drugs | RMB 8.809 bn | +16.38% | 63.16% of total pharma sales |
The 73.97% surge in non‑oncology innovative products signals successful diversification beyond Hengrui’s traditional oncology base, while innovative drugs now contribute nearly two‑thirds of pharmaceutical revenue — a structural shift in the company’s earnings mix.
Generic Business Continues Managed Retreat
- Generic drug sales fell 16.07% to RMB 5.139 billion, pressured by national and regional centralized procurement (VBP) policies.
- Hengrui proactively scaled back resource allocation to these products; centralized‑procurement risk continued to be absorbed.
- Generics’ share of total pharmaceutical sales dropped to 36.84% from 44.72% a year earlier.
Out‑Licensing Revenue Normalizes After High Base
- Out‑licensing collaboration revenue, now a routine operating line, totaled RMB 1.422 billion in 1H 2026.
- The figure primarily comprised RMB 1.176 billion recognized from the GSK collaboration based on progress of performance obligations, plus milestone payments from Braveheart Bio and others.
- The year‑earlier period’s RMB 1.991 billion reflected a high base from upfront payments — US$200 million from Merck & Co., Inc. and US$75 million from IDEAYA Biosciences — recognized when performance obligations were fulfilled.
Market Impact & Outlook
- Innovation Transition On Track: With R&D spending up nearly 19% and innovative drugs at 63% of pharma sales, Hengrui is cementing its pivot from volume‑based generics to high‑margin innovation.
- Diversification Payoff: Non‑oncology growth of 74% reduces reliance on a single therapeutic franchise and broadens the launch pipeline.
- Deal Flow as Earnings Lever: Recurring out‑licensing income — GSK progress revenue plus milestones — adds a volatile but increasingly institutionalized revenue stream that investors will watch alongside organic growth.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Hengrui’s innovation transition, product mix, and out‑licensing pipeline. Actual results may differ due to risks including centralized‑procurement policy changes, regulatory outcomes, collaboration progress, and market competition.-Fineline Info & Tech